Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Assets: 2014-2025

Historic Return on Assets for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Sep 2025 value amounting to -0.52%.

  • Viridian Therapeutics, Inc.\DE's Return on Assets fell 14.00% to -0.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.52%, marking a year-over-year decrease of 14.00%. This contributed to the annual value of -0.44% for FY2024, which is 8.00% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Return on Assets of -0.52% as of Q3 2025, which was up 5.69% from -0.55% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Return on Assets' 5-year high stood at -0.30% during Q4 2022, with a 5-year trough of -1.10% in Q2 2021.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Return on Assets averaged around -0.47%, with its median value being -0.44% (2025).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Return on Assets skyrocketed by 98bps in 2021, and later dropped by 28bps in 2023.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Return on Assets stood at -0.37% in 2021, then rose by 8bps to -0.30% in 2022, then fell by 28bps to -0.58% in 2023, then rose by 22bps to -0.36% in 2024, then declined by 14bps to -0.52% in 2025.
  • Its last three reported values are -0.52% in Q3 2025, -0.55% for Q2 2025, and -0.44% during Q1 2025.